PANCREAS Study Group
STUDY GROUP LEADERS
Fabrizio Di Benedetto (Modena University, Italy)
Orlando J. Torres (Maranhão Federal University, Brazil)
TITLE: Liver resection for synchronous metastasis from adenocarcinoma of the pancreas
The study focuses on patients with synchronous liver metastasis from pancreatic adenocarcinoma that underwent both pancreatic and liver resection. The control group is made up of patients with resectable or borderline resectable pancreatic adenocarcinoma and synchronous liver metastasis that were excluded from surgery. Short and long-term outcomes will be compared to evaluate the safety and efficacy of simultaneous liver and pancreatic resection.
The primary aim is to examine recurrence-free survival (RFS) and overall survival (OS) following surgical resection of synchronous hepatic metastases from PDAC, and to study the role of tumor burden and chemotherapy regimen on survival.
- No time interval limitation for recruitment
- No volume-based restriction for center eligibility
Patients of age >18, underwent surgery for pancreatic adenocarcinoma (duodenopancreatectomy, distal pancreatectomy, total pancreatectomy) and liver resection (major or minor) for synchronous metastasis, that received neoadjuvant and/or adjuvant chemotherapy.
The control group is made up of patients age >18 with resectable or borderline resectable pancreatic adenocarcinoma and synchronous liver metastasis that didn't undergo surgery.